Double Strike: Experts, with the Support of NovaMedica, Discuss New Opportunities for the Treatment of Sleep Disorders at the 2nd All-Russian Neurocongress

ONLY FOR HEALTHCARE PROFESSIONALS

Providing Russian patients with innovative drugs for the treatment of psychiatric and neurological disorders is a priority for NovaMedica (an investment project of Rusnano). The company’s development strategy is based on building up competencies in the development of unique drugs and organizing their production at the NovaMedica Innotech technology center.

Another important focus for ​​the company is informing the medical community about the availability of modern domestic drugs and the experience of their use in real clinical practice.

“Greater information transparency is needed to build trust in the achievements of domestic manufacturers. When the medical community understands the approaches that a pharmaceutical company applies to planning new scientific developments, observes consistent progress in research, has an opportunity to ensure that conditions are created for the production of high-quality medicines, and promptly receives information on the drug use experience, there comes confidence in the medicinal product,” says Elena LITVINOVA, CEO of NovaMedica.  

NovaMedica carries out extensive educational work among doctors to improve the diagnosis and treatment of psychiatric and neurological diseases. In particular, at one of the largest specialized medical events of federal significance in the field of neurology, the 2^nd All-Russian Neurocongress with international participation, regional- and federal-level experts shared knowledge and exchanged experience in introducing NovaMedica products into their practice.

With the support of NovaMedica, the workshop on “Modern Approaches to the Management of Patients with Neurological Diseases” of the scientific program of the Congress featured a report titled “Sleep Disorders: How Can a Neurologist Help?” presented by Anna LEBEDEVA, Doctor of Medical Sciences, Professor of the Department of Neurology, Neurosurgery and Medical Genetics, General Medicine Faculty, at the N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Head of the Neurology Organization and Methodology Division at the Research Institute for Healthcare and Medical Management of the Moscow Department of Health, member of the Presidium of the All-Russian Society of Neurologists, member of the Russian Anti-Epileptic League. 

Doctors estimate that 30% to 48% of adults experience sleep problems, with 10%–30% suffering from chronic insomnia¹. Almost 40% of Moscow residents experience drowsiness, difficulty falling asleep, or wake up in the middle of the night². Sleep disorders are a risk factor for many cardiovascular diseases, and they accompany most neurological and mental disorders. More than 120 participants of the workshop discussed modern comprehensive approaches to the treatment of sleep disorders, including eliminating the causes of comorbid conditions, ensuring proper sleep hygiene, and using cognitive behavioral therapy and pharmacotherapy. The specialists noted the relevance of the information presented in the report and expressed their gratitude for the opportunity to hear about the latest data on insomnia therapy from one of the country’s leading practitioners in the field.

In 2022, NovaMedica registered, patented and launched its own product Levroso® Long, an original drug for the treatment of sleep disorders in adults over 18 years of age, containing a fixed combination of extended-release diphenhydramine and melatonin.

The concept of the combination drug was suggested by leading clinical experts based on a study of the needs of patients suffering from insomnia. Detailed elaboration of the profile and development of the drug were carried out by the researchers and developers of NovaMedica.

¹ https://www.vedomosti.ru/gorod/townspeople/articles/chto-izbavit-ot-bessonitsi

² https://moskvichmag.ru/gorod/pochti-u-poloviny-moskvichej-est-problemy-so-snom/

For information:

The 2^nd All-Russian Neurocongress with international participation is held annually with the aim of improving and developing the medical care system in the field of neurology and implementing the state policy on modernization of health care, supporting the improvement of the quality of specialized care provided to the Russian citizens and the reduction of morbidity, mortality and disability of the population caused by neurological diseases. The organizers of the Congress are the Ministry of Health of the Russian Federation, the Federal Medical and Biological Agency, the Moscow Department of Health, the All-Russian Society of Neurologists, the National Stroke Association, the Federal Center for Brain and Neurotechnology of the Federal Medical and Biological Agency of Russia, the N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, and the Regional Public Organization of Disabled People “Human Health”.

THE PRODUCT HAS CONTRAINDICATIONS. CONSULT A SPECIALIST BEFORE USE